Literature DB >> 31219767

Serum IL-6 and sIL-6R in type 2 diabetes contribute to impaired capillary-like network formation.

Rian Q Landers-Ramos1,2,3, Jacob B Blumenthal2,3, Steven J Prior2,3,4.   

Abstract

We hypothesized that the serum from individuals with type 2 diabetes mellitus (T2DM) and impaired glucose tolerance (IGT) would reduce in vitro capillary-like network formation compared with normal glucose tolerance (NGT) serum and that this would occur along with higher serum concentrations of inflammatory cytokines and lower concentrations of angiogenic growth factors. Subjects were sedentary, older (55-65 yr) adults with NGT, IGT, or T2DM (n = 10/group) matched for body mass index. Human retroviral telomerized endothelial cells (HRVT-ECs) or coronary artery endothelial cells (CECs) were used in a capillary-like network formation assay using endothelial basal medium supplemented with 7.5% serum. Quantification of HRVT-EC network length indicated that serum from the T2DM group resulted in 32 and 35% lower network formation than when using serum from the NGT and IGT groups, respectively (P < 0.05). Serum from T2DM subjects resulted in CEC network formation that was 11 and 8% lower than when using serum from NGT and IGT subjects, respectively (P < 0.05). Analysis of serum cytokines indicated that IL-6 was 41% and 49% higher in the IGT and T2DM groups, respectively, compared with the NGT group (P < 0.05) and there was a trend for higher soluble interleukin-6 receptor (sIL-6R; P = 0.06) and IL-8 (P = 0.08) in the T2DM serum compared with NGT. The use of recombinant IL-6 and sIL-6R at concentrations detected in the T2DM serum also reduced capillary network formation compared with NGT concentrations (P < 0.05). These results suggest that IL-6 and sIL-6R present in the serum of T2DM individuals impair in vitro endothelial cell function across different cell lines. Our findings may have implications for the microvascular complications associated with T2DM.NEW & NOTEWORTHY Higher concentrations of serum factors, specifically Interleukin-6 and its soluble receptor found in individuals with type 2 diabetes (T2DM) appear to impair endothelial cell capillary-like network formation compared with those present in serum from individuals with impaired glucose tolerance and normal glucose tolerance. This may have implications for the vascular complications associated with T2DM.

Entities:  

Keywords:  IL-6; angiogenesis; cytokines; diabetes mellitus; impaired glucose tolerance

Year:  2019        PMID: 31219767      PMCID: PMC6732435          DOI: 10.1152/japplphysiol.00002.2019

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  42 in total

Review 1.  The role of pericytes in blood-vessel formation and maintenance.

Authors:  Gabriele Bergers; Steven Song
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

2.  Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue.

Authors:  Eva Chou; Izumi Suzuma; Kerrie J Way; Darren Opland; Allen C Clermont; Keiko Naruse; Kiyoshi Suzuma; Nancy L Bowling; Chris J Vlahos; Lloyd Paul Aiello; George L King
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

Review 3.  The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.

Authors:  Karl-Josef Kallen
Journal:  Biochim Biophys Acta       Date:  2002-11-11

4.  High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells.

Authors:  Naoki Makino; Toyoki Maeda; Masahiro Sugano; Shinji Satoh; Reiko Watanabe; Nobuyuki Abe
Journal:  J Diabetes Complications       Date:  2005 Nov-Dec       Impact factor: 2.852

5.  Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes.

Authors:  Andrew D Blann; Funmi M Belgore; Charles N McCollum; Stanley Silverman; Peck Lin Lip; Gregory Y H Lip
Journal:  Clin Sci (Lond)       Date:  2002-02       Impact factor: 6.124

6.  Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors.

Authors:  S Müller; S Martin; W Koenig; P Hanifi-Moghaddam; W Rathmann; B Haastert; G Giani; T Illig; B Thorand; H Kolb
Journal:  Diabetologia       Date:  2002-05-08       Impact factor: 10.122

7.  Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction.

Authors:  Thomas Nyström; Arne Nygren; Ake Sjöholm
Journal:  Clin Sci (Lond)       Date:  2006-06       Impact factor: 6.124

8.  Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance.

Authors:  K M Choi; J Lee; K W Lee; J A Seo; J H Oh; S G Kim; N H Kim; D S Choi; S H Baik
Journal:  Diabetes Res Clin Pract       Date:  2004-05       Impact factor: 5.602

9.  Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.

Authors:  Shih-Pei Huang; Ming-Shiang Wu; Chia-Tung Shun; Hsiu-Po Wang; Ming-Tsan Lin; Min-Liang Kuo; Jaw-Town Lin
Journal:  J Biomed Sci       Date:  2004 Jul-Aug       Impact factor: 8.410

Review 10.  Abnormal angiogenesis in diabetes mellitus.

Authors:  Alexandra Martin; Michael R Komada; David C Sane
Journal:  Med Res Rev       Date:  2003-03       Impact factor: 12.944

View more
  2 in total

1.  Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis.

Authors:  Xiongfeng Pan; Atipatsa C Kaminga; Shi Wu Wen; Aizhong Liu
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 2.  Emerging Roles of Myeloid-Derived Suppressor Cells in Diabetes.

Authors:  Shiqi Wang; Qian Tan; Yayi Hou; Huan Dou
Journal:  Front Pharmacol       Date:  2021-12-16       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.